Showing 6751-6760 of 7678 results for "".
- FDA Approves SciBase's Nevisense for Melanoma Detectionhttps://practicaldermatology.com/news/fda-approved-scibases-nevisense-for-melanoma-diagnosis/2458136/The FDA has approved the Scibase Pre-Market Approval (PMA) for Nevisense, a device for the early detection of malignant melanoma. According to the letter from the FDA the device is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melano
- HydroLotion Scores National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/hydrolotion-scores-national-eczema-association-seal-of-acceptance/2458138/Theraplex Company’s HydroLotion Daily Skin Moisturizer now has the National Eczema Association (NEA) Seal of Acceptance. The light-weight moisturizer for the face and body is hypoallergenic, noncomedogenic, and free of fragrances, preservatives
- Survey: Despite Knowledge, Parents Don't Drive Kids' Sunscreen Usehttps://practicaldermatology.com/news/survey-despite-knowledge-parents-dont-drive-kids-sunscreen-use/2458142/According to a new Neutrogena Survey conducted online by Harris Poll, more than 4 in 5 parents of children under 18 years old say their children do not wear sunscreen on a daily basis— despite over 9 in 10 Americans believing sunscreen is important for protecting a child’s health.
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe
- Wontech's Pico Laser Gets FDA Nodhttps://practicaldermatology.com/news/wontechs-pico-laser-gets-fda-nod/2458146/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- FDA Approves New Antibiotic for Skin Infectionshttps://practicaldermatology.com/news/fda-approves-new-antibiotic-for-skin-infections/2458149/The FDA has approved Melinta Therapeutics' Baxdela (delafloxacin) for adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathog
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- HED Research Fuels Understanding of Male Pattern Baldnesshttps://practicaldermatology.com/news/hed-research-fuels-understanding-of-male-pattern-baldness/2458162/The origins of hypohidrotic ectodermal dysplasia (HED) may help researchers get a better handle on the genetic underpinnings of common hair disorders. The findings appear in Nature Communications. About one in 5,000 to 10,000 people are thought to have HED, although this
- Murad Adds Two New Blemish-busting Products for Acne Awareness Monthhttps://practicaldermatology.com/news/murad-adds-two-new-products-for-acne-awareness-month/2458161/June is acne awareness month, and Murad is rolling out two anti-acne new products to help patients say goodbye to blemishes. The new Pore Extractor Pomegranate Mask ($38 from Murad.com) features volcanic clay, pomegranate extract and lactic aci
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients